Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.
November 17-19, 2022 | Washington, DC (National Harbor)
Make your plans to attend the SNMMI Fall Therapeutics Conference, November 17-19, 2022 at the Gaylord National Resort and Convention Center, moments from Washington, DC. This two-and-a-half-day event will explore the latest innovations and clinical applications in radiopharmaceutical therapy. Get notified when program information/registration become available.
January 26-28, 2023 | San Francisco, CA
The 2023 SNMMI Mid-Winter and ACNM Annual Meeting—January 26-28 in San Francisco, CA—will feature three educational tracks highlighting the latest innovations and techniques in the field, including a dedicated track on neuroimaging.
Now Open: ACNM invites you to submit an original clinical or scientific abstract for the opportunity to present your research during the 2023 SNMMI Mid-Winter and ACNM Annual Meeting.
The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.
For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.
For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.
Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!
In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.
SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.
The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.
SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.
The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.
SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors.
The new Quality in Nuclear Medicine Online Program is designed to help you understand the skill requirements vital to your quality of practice. Pharmacists (ACPE), Physicians and Physicists (AMA PRA Category 1 Credit™) credits available. Learn More »
On November 1, CMS released the 2023 Medicare Physician Fee Schedule and Hospital Outpatient Prospective payment Final Rules.
(Government Relations News)
A new molecular imaging radiotracer, Ga-68 PentixaFor, can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.
SNMMI is now accepting nominations for our 2023 Ones to Watch selections. We need your help in identifying and recognizing “ones to watch” in the coming years, as they work to shape the future of nuclear medicine and molecular imaging. Members can nominate someone they know—currently in training or who have completed their training within the last 10 years—whose actions, work, or studies have set them apart as a future thought leader in the field.
SNMMI is pleased to present our annual list of 30 early career professionals selected as “Ones to Watch” in 2022!
Visit SNMMI's—the leader in radiopharmaceutical therapy education and resources—therapy-focused web portal for members, researchers, the medical community, and patients.
This portal has been created as a repository for all things therapy, providing you with direct access to SNMMI's comprehensive content in one location. We encourage you to bookmark this page for direct access to therapy-related content, including:
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.